Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B Inhibitor, in Diffuse Cutaneous Systemic Sclerosis

Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B Inhibitor, in Diffuse Cutaneous Systemic Sclerosis
Recruiting
18 years - 90 years
All
Phase 1
2 participants needed
1 Location

Brief description of study

This study is being done to learn more about the safety of the study drug, AVID200, and to find out more about the effects of different study drug doses in people with scleroderma.  AVID200 is referred to as an investigational drug because it is in the early stages of development and has not been approved by the U.S. Food and Drug Administration, which means that it is not available to be prescribed or sold.  The study drug is given intravenously (in the vein) over 1 hour.  Study drug is given once every 2 weeks for a total of 3 doses.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Systemic Sclerosis,SSc,Scleroderma
  • Age: 18 years - 90 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 832173

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.